Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells.
Several epidemiological studies have provided evidence that administration of nonsteroidal anti-inflammatory drugs (NSAIDs) could have a prophylactic effect against some cancers such as sporadic colorectal cancer and leukemia. Indeed, various NSAIDs have been shown to induce apoptosis in malignant cells. We evaluated the effect of racemic Etodolac on proliferation and cell survival in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells. Etodolac decreased survival of Nalm-16 and Nalm-6 BCP-ALL cell lines and also decreased cell proliferation in Nalm-16 cell line. Ours findings indicate, for the first time to our knowledge, that Etodolac is cytotoxic and cytostatic for BCP-ALL cells.
de Souza Thiago
Leandro
L
Banco de Células do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, UFRJ, 21941-590 Cidade Universitária, Rio de Janeiro, Brazil. leandrothiago@terra.com.br
da Costa
Elaine Sobral
ES
Lopes
Daiana Vieira
DV
Borojevic
Radovan
R
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000494:pharmacology*; D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D054697:Cytostatic Agents / Q000494:pharmacology*; D017308:Etodolac / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; D013237:Stereoisomerism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000964:Antimetabolites, Antineoplastic; D054697:Cytostatic Agents; D017308:Etodolac